Analyst Has 4 Favorite Biotechnology Stocks to Buy Now
A new Merrill Lynch research report makes the case that four top biotech companies the firm covers have some powerful catalysts that could drive performance this year.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 142
Elizabeth Holmes and Theranos Charged With Massive Fraud
The SEC has finally charged Silicon Valley-based private company Theranos, along with its founder and CEO Elizabeth Holmes and former President Ramesh “Sunny” Balwani, with a massive fraud.
Bellicum Bounces With Cancer Drug Data
Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) shares made a solid gain on Tuesday after the company announced interim clinical data of BPX-501 in pediatric patients with acute myeloid leukemia (AML) and primary immunodeficiencies (PIDs).
Why Proteostasis Therapeutics Shares Are Skyrocketing
Proteostasis Therapeutics saw its shares skyrocket going into Tuesday’s session following a pivotal decision from the FDA for the firm’s cystic fibrosis therapy.
Is Anthera Dead in the Water?
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) saw its shares get absolutely crushed in Monday’s session following missed results in a late-stage study. Specifically, the company said that Sollpura did not meet the non-inferiority margin of…
Major Biotechs: Tough Call for Short Sellers
The February 28 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Major Pharma Sees Big Drop in Short Interest
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Why Now Seems Like the Best Time for a Global Blood Therapeutics Secondary Offering
Global Blood Therapeutics saw its shares pull back on Friday after the firm announced that it would be conducting a secondary offering.
5 Top Jefferies Health Care Picks Have Big-Time Potential
These five top companies with different health care businesses all can provide nice exposure to the sector in growth portfolios. All are rated Buy at Jefferies and make sense now.
Merrill Lynch’s Top Biotech Acquisition Targets in 2018
Merrill Lynch has taken a look at the biotech industry and made a few picks that could play out in 2018.
Why Vascular Biogenics Is Getting Crushed
Vascular Biogenics watched its shares get absolutely crushed on Thursday after the firm reported top-line results for its late-stage trial in patients with recurrent glioblastoma.
Why Cigna’s $50 Billion Offer for Express Scripts Is a Bad Deal
Health insurer Cigna has agreed to acquire pharmacy benefits management firm Express Scripts for $67 billion, including debt. Is consolidation in the health care sector beginning to reach antitrust territory?
Is It Finally Time to Buy Into Mylan?
Mylan has been through the ringer over the past couple of years, but by the looks of it, this stock could be turning around.
Does Deutsche Bank Finally Have It Right on Valeant?
Valeant Pharmaceuticals saw its shares make a handy gain on Monday after Deutsche Bank upgraded the stock.
Why Dermira Shares Are Getting Crushed
Dermira watched its shares absolutely collapse early on Monday after the firm reported disappointing results from its late-stage trials in patients with acne vulgaris.